Patents Assigned to Cubist Pharmaceuticals, Inc.
-
Publication number: 20130065874Abstract: This disclosure relates to the treatment of intrapulmonary bacterial infections, including treatment of nosocomial pneumonia lung infections with pharmaceutical compositions containing the cephalosporin ceftolozane.Type: ApplicationFiled: September 7, 2012Publication date: March 14, 2013Applicant: Cubist Pharmaceuticals, Inc.Inventors: Gurudatt A. Chandorkar, Jennifer A. Huntington, Tara Parsons, Obiamiwe C. Umeh
-
Publication number: 20120270772Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.Type: ApplicationFiled: November 23, 2010Publication date: October 25, 2012Applicant: CUBIST PHARMACEUTICALS, INC.Inventors: Sandra O'Connor, Sophie Sun, Gaauri Naik
-
Patent number: 8129342Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.Type: GrantFiled: September 22, 2010Date of Patent: March 6, 2012Assignee: Cubist Pharmaceuticals, Inc.Inventors: Thomas J. Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul D. Lynch, Maurizio Zenoni, Auro R. Tagliani
-
Patent number: 8058238Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.Type: GrantFiled: April 24, 2007Date of Patent: November 15, 2011Assignee: Cubist Pharmaceuticals, Inc.Inventors: Thomas Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul Lynch, Maurizio Zenoni, Auro Tagliani
-
Patent number: 8003673Abstract: Daptomycin can be used for biofilm treatment (particularly central venous catheter salvage for S. epidermidis infected catheters). Catheter salvage with daptomycin shows rapid cidality, activity against stationary phase bacteria, and penetration and activity in biofilms. The present inventions provide formulations, methods, and articles of manufacture useful for biofilm treatment or catheter salvage involving daptomycin. Particular formulations include daptomycin in lactated Ringer's solution having a rapid kill curve against the bacteria of the biofilm.Type: GrantFiled: May 31, 2006Date of Patent: August 23, 2011Assignee: Cubist Pharmaceuticals, Inc.Inventors: Jeffrey Alder, Jared Silverman, Lawrence Mortin, Andrew Van Praagh
-
Publication number: 20090155234Abstract: A method for detecting a mutation related to the gene encoding MxA. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human MxA, including antisense oligonucleotides, methods, and compositions specific for human MxA, are also provided.Type: ApplicationFiled: August 25, 2006Publication date: June 18, 2009Applicant: Cubist Pharmaceuticals, Inc.Inventors: Charles L. Magness, Shawn P. Iadonato, Christina A. Scherer, Phillip Campion Fellin, Kathryn V. Steiger
-
Patent number: 7527807Abstract: The present invention provides compositions and methods for increasing absorption of antibacterial agents, particularly third generation cephalosporin antibacterial agents, in oral dosage solid and/or suspension forms. Specifically, the composition is comprised of a biopolymer that is preferably swellable and/or mucoadhesive, a antimicrobial agent, and a cationic binding agent contained within the biopolymer such that the binding agent is tonically bound or complexed to at least one member selected from the group consisting of the biopolymer and the antimicrobial agent.Type: GrantFiled: June 22, 2001Date of Patent: May 5, 2009Assignee: Cubist Pharmaceuticals, Inc.Inventors: Seung-Ho Choi, Jeoung-Soo Lee, Dennis Keith
-
Publication number: 20080318267Abstract: The present invention provides cells having more than two drug resistance genes and at least two different resistance genes that have been recombined into the chromosome of a cell. It also teaches the processes for preparing cells by recombining two or more different drug resistance genes into the chromosome of a cell. The invention further shows a screening method using the cells of described herein that may be used to accomplish high throughput screening of, among other things, natural products and/or whole cells isolated from the environment.Type: ApplicationFiled: December 16, 2005Publication date: December 25, 2008Applicant: Cubist Pharmaceuticals, Inc.Inventors: Richard H. Baltz, Catherine Monahan, Christopher Murphy, Julia Penn, Daniel Ritz, Stephen Wrigley
-
Publication number: 20080213366Abstract: The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described.Type: ApplicationFiled: April 27, 2006Publication date: September 4, 2008Applicant: Cubist Pharmaceuticals, IncInventors: Walter G. Gowan Jr, Dennis D. Keith, Sandra O'Connor
-
Patent number: 7408025Abstract: The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.Type: GrantFiled: December 15, 2000Date of Patent: August 5, 2008Assignee: Cubist Pharmaceuticals, Inc.Inventors: Jason Hill, Ian Parr, Michael Morytko, Jim Siedlecki, Xiang Yang Yu, Jared Silverman, Dennis Keith, John Finn, Dale Christensen, Tsvetelina Lazarova, Alan D. Watson, Yan Zhang
-
Publication number: 20080154514Abstract: A technique is disclosed for classifying a population of subjects into various sub-populations for a selected biological condition. Patients are categorized in accordance with numeric scores for a affected status for the selected biological condition and a risk status for the selected biological condition. The numeric scores for an overall population are determined in advance for the selected biological condition. Medical test results, including genetic tests, and risk factors are numerically scored and may further be weighted in accordance with their relevance in determining affected status and risk. Medical test results and medical histories for individual subjects within the population may then automatically be scored in accordance with the predefined characteristics. The numerical scores for affected status and risk status may be stored in a data structure, such as a database.Type: ApplicationFiled: November 16, 2007Publication date: June 26, 2008Applicant: Cubist Pharmaceuticals, Inc.Inventors: Charles L. Magness, Shawn P. Iadonato
-
Patent number: 7335726Abstract: The present invention provides daptomycin stereoisomeric compounds, methods and intermediates for preparing daptomycin and daptomycin stereoisomoeric compounds, as well as pharmaceutical compositions of these compounds and methods of using these compositions as antibacterial agents.Type: GrantFiled: June 6, 2006Date of Patent: February 26, 2008Assignee: Cubist Pharmaceuticals, Inc.Inventors: Michael Morytko, Yanzhi Zhang, Michael Jung, John Finn
-
Patent number: 7335725Abstract: The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.Type: GrantFiled: May 4, 2005Date of Patent: February 26, 2008Assignee: Cubist Pharmaceuticals, Inc.Inventors: Jason Hill, Ian Parr, Michael Morytko, Jim Siedlecki, Xian Yang Yu, Jared Silverman, Dennis Keith, John Finn, Dale Christensen, Tsvetelina Lazarova, Alan D. Watson, Yan Zhang
-
Patent number: 7262268Abstract: The present invention provides daptomycin stereoisomeric compounds, methods and intermediates for preparing daptomycin and daptomycin stereoisomoeric compounds, as well as pharmaceutical compositions of these compounds and methods of using these compositions as antibacterial agents.Type: GrantFiled: August 6, 2002Date of Patent: August 28, 2007Assignee: Cubist Pharmaceuticals, Inc.Inventors: Michael Morytko, Yanzhi Zhang, Michael Jung, John Finn
-
Patent number: 7235651Abstract: Genes and proteins involved in the biosynthesis of lipopeptides by microorganisms, in particular the nucleic acids forming the biosynthetic locus for the A54145 lipopeptide from Streptomyces fradiae and the A54145-like lipopeptide from Streptomyces refuineus. These nucleic acids can be used to make expression constructs and transformed host cells for the production of lipopeptides. The genes and proteins allow direct manipulation of lipopeptides and related chemical structures via chemical engineering of the proteins involved in the biosynthesis of A54145.Type: GrantFiled: December 24, 2002Date of Patent: June 26, 2007Assignee: Cubist Pharmaceuticals, Inc.Inventors: Chris M. Farnet, Alfredo Staffa, Emmanuel Zazopoulos
-
Patent number: 6911525Abstract: The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.Type: GrantFiled: December 15, 2000Date of Patent: June 28, 2005Assignee: Cubist Pharmaceuticals, Inc.Inventors: Jason Hill, Ian Parr, Michael Morytko, Jim Siedlecki, Xian Yang Yu, Jared Silverman, Dennis Keith, John Finn, Dale Christensen, Tsvetelina Lazarova, Alan D. Watson, Yan Zhang
-
Patent number: 6852689Abstract: The invention provides methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin administration at a dosing interval of 24 hours or greater. This long dosing interval minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which is related to daptomycin's efficacy. The invention also provides methods of administering lipopeptide antibiotics other than daptomycin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity. The invention also provides methods of administering quinupristin/dalfopristin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that dos not result in muscle toxicity.Type: GrantFiled: February 20, 2002Date of Patent: February 8, 2005Assignee: Cubist Pharmaceuticals, Inc.Inventors: Frederick B. Oleson, Jr., Francis P. Tally
-
Patent number: 6846625Abstract: The invention comprises methods useful within a larger process for identifying compounds and/or designing further compounds with activity to produce a desired phenotype (for example, growth inhibition) in cells whose target cell component is the subject of certain studies to identify such compounds. The invention employs constructed cells comprising a regulable gene encoding a biomolecule which modulates (inhibits or activates) in vivo the function of a target component of the cell which can be an enzyme for example. The process incorporates methods for identifying biomolecules that bind to a chosen target cell component in vitro, methods for identifying biomolecules that also bind to the chosen target and modulate its function intracellularly, causing a phenotypic effect.Type: GrantFiled: January 8, 1999Date of Patent: January 25, 2005Assignee: Cubist Pharmaceuticals, Inc.Inventors: Francis P. Tally, Jianshi Tao, Philip A. Wendler, Gene Connelly, Paul L. Gallant
-
Patent number: 6794490Abstract: The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.Type: GrantFiled: December 15, 2000Date of Patent: September 21, 2004Assignee: Cubist Pharmaceuticals, Inc.Inventors: Jason Hill, Ian Parr, Michael Morytko, Jim Siedlecki, Xian Yang Yu, Jared Silverman, Dennis Keith, John Finn, Dale Christensen, Tsvetelina Lazarova, Alan D. Watson, Yan Zhang
-
Patent number: 6784203Abstract: A 5,6-dihydro-&agr;-pyrone of formula (I) wherein R is CO2H or CH3 and, when R is CO2H, a pharmaceutically or veterinarily acceptable salt thereof. Processes for producing compounds of formula (I) and their use as cytokine production inhibitors.Type: GrantFiled: June 7, 2001Date of Patent: August 31, 2004Assignee: Cubist Pharmaceuticals, Inc.Inventors: Stephen Keith Wrigley, Sangeeta Bahl, Roya Mansour Sadeghi Guilani, Michael Moore, Werner Albert Katzer, Steven Michael Martin, David Andrew Kau, Andrew Jonathan Whiting, Neil Robinson, Martin Alistair Hayes, Thomas Haydn Mander